Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Werte in diesem Artikel
Accuray (ARAY) reported $116.17 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 8.3%. EPS of $0.02 for the same period compares to -$0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $110.95 million, representing a surprise of +4.71%. The company delivered an EPS surprise of +300.00%, with the consensus EPS estimate being -$0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Accuray performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net revenue- Services: $54.99 million versus the two-analyst average estimate of $56.85 million. The reported number represents a year-over-year change of -1.3%. Net revenue- Products: $61.19 million versus the two-analyst average estimate of $53.80 million. The reported number represents a year-over-year change of +18.7%. Gross Margin- Products: $26.64 million compared to the $18 million average estimate based on two analysts. Gross Margin- Services: $15.26 million versus $18.35 million estimated by two analysts on average. View all Key Company Metrics for Accuray here>>>Shares of Accuray have returned +6.4% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accuray Incorporated (ARAY): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf Accuray
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Accuray
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Accuray IncShs
Analysen zu Accuray IncShs
Datum | Rating | Analyst | |
---|---|---|---|
30.11.2017 | Accuray Buy | Lake Street | |
22.12.2015 | Accuray Sector Perform | RBC Capital Markets | |
01.05.2015 | Accuray Buy | Dougherty & Company LLC | |
12.01.2015 | Accuray Outperform | Northland Capital | |
06.11.2007 | Accuray günstig bewertet | Global Biotech Investing |
Datum | Rating | Analyst | |
---|---|---|---|
30.11.2017 | Accuray Buy | Lake Street | |
01.05.2015 | Accuray Buy | Dougherty & Company LLC | |
12.01.2015 | Accuray Outperform | Northland Capital | |
06.11.2007 | Accuray günstig bewertet | Global Biotech Investing |
Datum | Rating | Analyst | |
---|---|---|---|
22.12.2015 | Accuray Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Accuray IncShs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen